Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does ERYTHROMYCIN Cause Malignant neoplasm progression? 10 Reports in FDA Database

Visibly Younger Skin in Weeks

Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.

Discover Synevra

According to the FDA Adverse Event Reporting System (FAERS), 10 reports of Malignant neoplasm progression have been filed in association with ERYTHROMYCIN (Erythromycin). This represents 0.1% of all adverse event reports for ERYTHROMYCIN.

10
Reports of Malignant neoplasm progression with ERYTHROMYCIN
0.1%
of all ERYTHROMYCIN reports
3
Deaths
6
Hospitalizations

How Dangerous Is Malignant neoplasm progression From ERYTHROMYCIN?

Of the 10 reports, 3 (30.0%) resulted in death, 6 (60.0%) required hospitalization, and 2 (20.0%) were considered life-threatening.

Is Malignant neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for ERYTHROMYCIN. However, 10 reports have been filed with the FAERS database.

What Other Side Effects Does ERYTHROMYCIN Cause?

Drug hypersensitivity (3,813) Nausea (560) Drug ineffective (502) Vomiting (497) Rash (471) Hypersensitivity (401) Diarrhoea (378) Urticaria (361) Dyspnoea (344) Fatigue (344)

What Other Drugs Cause Malignant neoplasm progression?

PEMBROLIZUMAB (10,111) NIVOLUMAB (9,363) ENZALUTAMIDE (4,696) CARBOPLATIN (4,177) EVEROLIMUS (3,789) PACLITAXEL (3,484) LETROZOLE (3,445) IPILIMUMAB (3,296) FULVESTRANT (3,221) LENVATINIB (2,929)

Which ERYTHROMYCIN Alternatives Have Lower Malignant neoplasm progression Risk?

ERYTHROMYCIN vs ERYTHROMYCIN ETHYLSUCCINATE ERYTHROMYCIN vs ERYTHROMYCIN LACTOBIONATE ERYTHROMYCIN vs ERYTHROPOIETIN ERYTHROMYCIN vs ESCHERICHIA COLI ERYTHROMYCIN vs ESCITALOPRAM

Related Pages

ERYTHROMYCIN Full Profile All Malignant neoplasm progression Reports All Drugs Causing Malignant neoplasm progression ERYTHROMYCIN Demographics